Ani Pharmaceuticals Inc. buy tamam
Summary
This prediction ended on 08.04.16 with a price of €40.59. With a performance of -9.30%, the BUY prediction for Ani Pharmaceuticals Inc. by tamam closed slightly in the red. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Ani Pharmaceuticals Inc. | 2.564% | 2.564% | 38.249% | 109.790% |
| iShares Core DAX® | -1.226% | 2.804% | 14.933% | 16.561% |
| iShares Nasdaq 100 | -1.845% | 2.732% | 26.075% | 54.743% |
| iShares Nikkei 225® | -1.132% | -2.218% | 5.361% | 4.560% |
| iShares S&P 500 | -0.980% | 1.883% | 22.727% | 45.760% |
Comments by tamam for this prediction
In the thread Ani Pharmaceuticals Inc. diskutieren
tamam stimmt der fundamentalen Bewertung mit dem Ergebnis 'unterbewertet' zu
This company develops, manufactures and markets both branded and generic
prescription drugs. This under covered drug play is headquartered in
Minnesota and has a market capitalization of approximately $550 million.
ANI Pharmaceuticals is pursuing a well-rounded approach that meshes
accretive acquisitions with internal product development. This strategy
has delivered impressive earnings and revenue growth for several years
and I expect that to continue into the foreseeable future.
Revenues are currently tracking to 50% growth year-over-year. Depending
on new product rollout, the company should post another 40% increase in
sales in FY2014. After posting earnings of just over $1.10 a share in
FY2014, the current consensus has ANI earning $2.40 to $2.50 a share
this year and over $3.25 a share in FY2016. The company has a solid
balance sheet and the stock goes for just over 15 times next year's
expected profits. That is right in line with the overall market multiple
despite ANI's far superior growth prospects.